Doni Bloomfield

Doni Bloomfield is an Associate Professor of Law at Fordham Law School. He teaches and writes in the areas of intellectual property, antitrust, and health law. His research examines the role the law plays in encouraging technological progress while reducing risk, both to health and economic well-being. His recent scholarship has studied the relationship between market competition and supply resilience, the application of export controls to biosecurity risks, and the intersection of FDA and patent law. His work has been published in the Antitrust Law Journal, BMJ, JAMA, JAMA Internal Medicine, and elsewhere.

Prior to joining Fordham in 2024, Bloomfield was a Senior Research Associate at Johns Hopkins Bloomberg School of Public Health’s Center for Health Security and a postdoctoral fellow at the Program on Regulation, Therapeutics, and Law at Harvard Medical School. He served as a law clerk to Judge Timothy B. Dyk of the Federal Circuit and Judge Patricia A. Millett of the D.C. Circuit.

Bloomfield holds a J.D. from Yale Law School and a B.A. in economic history from the University of Chicago. Before law school, Bloomfield was a biotechnology reporter for Bloomberg News in Boston.

Representative Publications

AI and Biosecurity: The Need for Governance, 385 Science 831 (2024) (with Jaspreet Pannu, Alex W. Zhu, Madelena Y. Ng, Ashley Lewis, Eran Bendavid, Steven M. Asch, Tina Hernandez-Boussard, Anita Cicero, and Tom Inglesby)

Competition and Risk, 86 Antitrust Law Journal 63 (2024) 

Improving the Quality of Drug Patents with International Awareness, 377 BMJ E1 (2022) (with Zhigang Liu and Aaron S. Kesselheim) (lead author)

Extending Drug Monopolies by Patenting Safe Drug Use, 182 JAMA Internal Med. 245 (2022) (with Bryan S. Walsh and Aaron S. Kesselheim) (lead author)

Characteristics of Clinical Trials Evaluating Biosimilars Treating Cancer: Systematic Review and Meta-Analysis, 8 JAMA Oncology 537 (2022) (with Elvira D’Andrea, Sarosh Nagar, and Aaron S. Kesselheim) (lead author)

Patents and Exclusivities on Inhalers for Asthma and COPD, 1986-2020, 41 Health Affairs 787 (2022) (with William B. Feldman, Reed F. Beall, and Aaron S. Kesselheim)

Brand-name Market Exclusivity for Nebulizer Therapy to Treat Asthma and COPD, 40 Nature Biotechnology 1319 (2022) (with William B. Feldman, Reed F. Beall, and Aaron S. Kesselheim)

A Court Decision on “Skinny Labeling”: Another Challenge for Less Expensive Drugs, 326 JAMA 1371 (2021) (with Bryan S. Walsh and Aaron S. Kesselheim)